EVISTA Drug Patent Profile

Which patents cover Evista, and when can generic versions of Evista launch?

Evista is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in EVISTA is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evista

A generic version of EVISTA was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4^th, 2014.

Summary for EVISTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	4,367
Drug Prices:	Drug price information for EVISTA
What excipients (inactive ingredients) are in EVISTA?	EVISTA excipients list
DailyMed Link:	EVISTA at DailyMed

See drug prices for EVISTA

See drug sales revenues for EVISTA

Recent Clinical Trials for EVISTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 4
Shanghai Mental Health Center	Phase 4
Mayo Clinic	Phase 2

See all EVISTA clinical trials

Pharmacology for EVISTA

Drug Class	Estrogen Agonist/Antagonist
Mechanism of Action	Selective Estrogen Receptor Modulators

US Patents and Regulatory Information for EVISTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	AB	RX	Yes	Yes

Expired US Patents for EVISTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,811,120
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	8,030,330
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	5,731,327
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	4,418,068

International Patents for EVISTA

See the table below for patents covering EVISTA around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	320894
Brazil	9504059
World Intellectual Property Organization (WIPO)	9630361
Japan	2013166797	BENZOTHIOPHENES, FORMULATIONS CONTAINING THE SAME, AND METHODS

Supplementary Protection Certificates for EVISTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0584952	980044	Netherlands		PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
0584952	1/1999	Austria		PRODUCT NAME: RALOXIFEN ODER DESSEN PHARMEZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/98/073/001- EU/1/98/073/004 19980805
0584952	SPC/GB98/048	United Kingdom		PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805
0584952	99C0004	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: EVISTA (Raloxifene)

Last updated: January 17, 2026

---

Executive Summary

EVISTA (raloxifene), developed and marketed by Eli Lilly and Co., is a selective estrogen receptor modulator (SERM) primarily approved for osteoporosis prevention and breast cancer risk reduction in postmenopausal women. Despite its established indications, the drug operates within a complex market backdrop characterized by evolving regulatory landscapes, competitive therapies, and shifting disease prevalence.

Financial growth for EVISTA has experienced shifts driven by patent expirations, generic competition, and strategic repositioning. The current trajectory indicates a transition towards off-label uses and a potential future focus on niche indications, though market uptake remains challenged by newer therapeutics and biosimilars.

This analysis details the current market landscape, key drivers influencing EVISTA’s financial performance, competitive positioning, forecasted trends, and strategic considerations for stakeholders.

---

1. Market Overview and Historical Performance

Parameter	Details
Initial Approval	May 1997 (FDA, U.S.)
Primary Indications	Osteoporosis in postmenopausal women; reduction of invasive breast cancer risk (2012 amendment)
Peak Sales (Estimated)	~$700 million (by 2006)
Patent Expiration	2014 (U.S., 17 years from approval)
Market Share (Pre-Gen release)	Estimated at 30% for osteoporosis drugs in 2006

Note: EVISTA’s sales peaked prior to patent expiry, with subsequent decline owing to generics.

---

2. Market Drivers

a. Epidemiological Trends and Demographics

Factor	Impact	Data/Source
Global Postmenopausal Population	Increasing demand for osteoporosis therapies	WHO (2021): >1 billion women age >50 worldwide
Osteoporosis Prevalence	1 in 3 women over 50 suffer fractures	NIH (2018)
Breast Cancer Incidence	1.7 million new cases annually	GLOBOCAN (2020)

b. Regulatory Environment

• FDA Approvals & Label Expansion: Originally approved for osteoporosis, later gained approval for breast cancer risk reduction (2012).
• Off-label Use: Limited, but explored in other hormone-related conditions, affecting market dynamics.

c. Competitive Landscape

Key Competitors	Therapies	Market Share (2022)	Notes
Bisphosphonates	Alendronate, Risedronate	~60%	First-line for osteoporosis; cheaper generics
Selective Estrogen Receptor Modulators (SERMs)	Tamoxifen	Smaller niche	Used for breast cancer prevention
Denosumab (Prolia)	Monoclonal antibody	Increasing	Newer, higher cost, preferred for some osteoporosis cases
Bazedoxifene	Newer SERM	Emerging	Potential alternative

d. Patent and Market Entry of Biosimilars and Generics

• Generic raloxifene launched post-2014, reducing EVISTA’s price and sales.
• Bios_macro potential for further off-patent therapy erosion.

---

3. Financial Trajectory and Sales Forecasts

Timeline	Event/Trend	Projected Revenue Impact
2014	Patent expiration, first generics release	Sharp decline (~50%) in sales
2015-2017	Post-generic competition	Decline stabilizes at ~€150M/year
2018-2022	Market saturation; niche uses	Stabilization at ~$100M
2023-2026	Potential off-label expansion, generic erosion	Expected continued decline, possible resurgence with new indications or combination therapies

Forecast (2023-2026):	Year	Estimated Sales (USD Millions)	CAGR	Assumptions
2023	80	-10%	Generic competition persists
2024	72	-10%	Off-label uses maintain niche
2025	65	-9.7%	Off-label growth restricted
2026	58	-10.8%	Market contraction continues

Note: These figures are estimates, assuming no significant label expansion or disruptive innovation.

---

4. Strategic Considerations

• Repositioning Strategies: Off-label use expansion, especially in early-stage breast cancer prevention or osteoporosis combined with other modalities.
• Regulatory Pathways: Potential for supplemental indications via accelerated approval pathways.
• Partnership & Licensing: Collaborations for biosimilar development or new formulation regimes.
• Pricing Strategies: To counteract generic erosion, premium pricing could be maintained for specific niche indications or combination therapies.

---

5. Comparative Analysis with Adjacent Therapies

Aspect	EVISTA	Denosumab (Prolia)	Bazedoxifene
Mechanism	SERM	RANKL inhibitor, monoclonal antibody	SERM
Indications	Osteoporosis, breast cancer risk reduction	Osteoporosis, bone metastases	Osteoporosis
Market Share (2022)	Declining	Growing	Emerging
Pricing (USD)	~$80-120/month (brand)	~$150-200/month	~$70-100/month
Patent Status	Expired (generics available)	Patent expiry pending	Under patent protection

---

6. Policy and Regulatory Influences

Category	Regulation/Policy	Impact on EVISTA
Pricing & Reimbursement	Variable; driven by cost-effectiveness analyses	Influences uptake, especially post-generic entry
Off-label Promotion Laws	Stringent	Limits off-label use expansion strategies
Biosimilar Regulations	Evolving	May accelerate generic/biosimilar penetration

---

7. Future Outlook and Strategic Opportunities

• Niche Market Focus: Targeting specific high-risk groups or rare indications.
• Combination Therapies: Exploring pairing with other osteoporosis or cancer drugs.
• Innovative Delivery: Development of long-acting formulations or biosimilars.
• Digital & Data Analytics: Utilizing real-world evidence to identify off-label potentials.

---

Key Takeaways

• EVISTA's sales peaked pre-2014, with a significant subsequent decline due to patent expiry and generics.
• Current revenues stabilize in the low hundreds of millions, primarily driven by niche uses.
• The competitive landscape is dominated by bisphosphonates and newer agents like denosumab.
• Strategic repositioning and potential label extensions could influence future growth trajectories.
• Stakeholders should monitor biosimilar regulations, off-label use trends, and emerging combination therapies for prospects.

---

FAQs

Q1: How does EVISTA compare to newer osteoporosis treatments like denosumab?
A1: While EVISTA functions as a SERM, denosumab is a monoclonal antibody targeting RANKL, offering higher efficacy in some cases. Denosumab has gained market share due to superior outcomes in fracture risk reduction but at a higher cost.

Q2: What impact did patent expiry have on EVISTA’s sales?
A2: Patent expiry in 2014 led to immediate generic competition, causing approximately a 50% reduction in sales and accelerating market share erosion.

Q3: Are there regulatory pathways to extend EVISTA's market life?
A3: Yes, pathways include supplemental indications, convenience formulations, or combination approvals, contingent on clinical trial evidence and regulatory agency acceptance.

Q4: What potential off-label uses could revive EVISTA’s revenue?
A4: Off-label applications such as prevention strategies in high-risk populations or adjunct therapy in hormone receptor-positive cancers could offer growth avenues if supported by clinical data.

Q5: What role do biosimilars play in EVISTA's future?
A5: While biosimilars are not applicable to small molecules like raloxifene directly, generic versions significantly affect pricing and market share, requiring strategic adaptation from Lilly.

---

References

1. U.S. Food and Drug Administration (FDA). (1997). EVISTA (raloxifene) approval documents.
2. WHO. (2021). Global estimates on osteoporosis prevalence.
3. NIH. (2018). Osteoporosis overview.
4. GLOBOCAN. (2020). Global cancer statistics.
5. Eli Lilly and Co. Annual Reports (2006-2022).
6. Market Research Future. (2022). Osteoporosis therapeutics market analysis.
7. FDA. (2012). Approval supplement for EVISTA.
8. IMS Health. (2022). Pharmaceutical sales data.

---

In conclusion, EVISTA remains a niche but relevant player within the osteoporosis and breast cancer prevention markets. Its financial trajectory will depend heavily on strategic innovation, market receptivity to new indications, and competitive responses to generics and biosimilars. Stakeholders must navigate an evolving landscape shaped by regulatory, clinical, and economic forces to optimize EVISTA's future value.

---